Development and validation of UV/VIS spectroscopy method for determination of atezolizumab in pharmaceutical products

Meliha Ekinci¹, Hasan Akbaba², Ralph Santos-Oliveira³, Derya Ilem-Ozdemir¹

¹Department of Radiopharmacy, Faculty of Pharmacy, Ege University, Bornova, Izmir, Turkey.
²Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Ege University, Bornova, Izmir, Turkey.
³Laboratory of Nanoradiopharmaceuticals, Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro, Brazil.

ABSTRACT

Aim: The aim of this study was to develop and validate a simple, fast, and reliable UV visible methodology for the determination of atezolizumab in pharmaceutical products.

Methods: The maximum wavelength of atezolizumab was determined using a UV/Vis spectrum and the calibration curve has been established. Validation studies were carried out to determine the reliability of the spectrophotometer method used in quantification of pharmaceutical products.

Results: According to the experimental data, the developed method was linear in a range varying from 0.10 to 1.50 mg.mL⁻¹ determined by 6 individuals calibrations points. The r² value was 0.9995 indicating a 99.95% correlation in linearity and precision. The robustness showed good and similar values and the limit of detection and limit of quantification were 0.005 mg.mL⁻¹ and 0.018 mg.mL⁻¹, respectively.

Conclusion: The data corroborates the reliability as applicability of the developed UV/Vis spectroscopy method for quantitatively determining the amount of atezolizumab in pharmaceutical products.

Key words Atezolizumab, monoclonal antibody, UV/Vis spectroscopy, validation, pharmaceutical products.

Introduction

Atezolizumab is a monoclonal antibody and has been approved by FDA for non-small cell lung cancer, metastatic urothelial carcinoma and triple negative breast cancer [1]. Preclinical studies showed that atezolizumab has a dose-dependent pharmacokinetic profile in intervals of dose from 0.5 to 5.0 mg.kg⁻¹. Nonetheless in higher dose (5–20 mg.kg⁻¹) a linear behavior is observed [2]. The therapeutic protocol recommends a dose of 1200 mg (approximately 15 mg.kg⁻¹) given over 1-h by intravenous infusion every 21 d. Although the therapeutic used approved, atezolizumab shows a higher number of adverse reactions, which includes: fatigue, cough, decreased appetite, dyspnea, musculoskeletal pain, constipation, nausea, pyrexia, diarrhea, arthralgia, rash, anemia, lymphocytopenia, hypoalbuminemia, hyponatremia, elevated alkaline phosphatase concentrations, elevated ALT/AST concentrations, hypophosphatemia and hypomagnesemia [3].

In recent years, monoclonal antibodies has been used in several clinical approaches including cancer therapy [4-7], chronic diseases [8-11] and many other applications [12-14] and
researchers round the world can design monoclonal antibodies to a specific target, such as overexpressed tumor proteins. One of the main issues regarding monoclonal antibodies is the precise determination. Although, there are several techniques used for monoclonal antibodies quantification most of them are expensive or take a long time to be processed [15]. Thus, fast, reliable and cheap techniques as UV spectrophotometry [16] to quantify precisely monoclonal antibodies are required and important technological approach, especially for pharmaceutical products. Regarding the atezolizumab, there is no UV spectrophotometry methodology published for the quantification of atezolizumab in pharmaceutical preparations. The methodologies found in literature to quantify this monoclonal antibody are: reverse – phase separation high performance liquid chromatography (RP-HPLC) [17], capillary zone electrophoresis (CZE) [18], two-dimensional liquid chromatography-tandem mass spectrometry (2D-LC-MS/MS) [19] and ion mobility mass spectrometry (IM-MS) [20]. The aim of our study was to develop a rapid, accurate and reliable UV/Vis method, with a simple, repeatable and inexpensive technique for the quantitative determination of atezolizumab in pharmaceutical products.

**Materials and methods**
This study was supported by The Scientific and Technological Research Council of Turkey (TUBITAK-220/S/361) within the scope of PhD thesis of Meliha Ekinci.

**Materials:** Atezolizumab (Tecentriq) was obtained from La Roche/Genentech. The saline solution (0.9% sodium chloride solution) was obtained from Intermountain Life Sciences, LLC. UV quartz spectra cuvette was obtained from Hellma GmbH, Germany.

**UV/Vis Spectrum:** The maximum wavelength was determined using a UV/Vis spectrum (Beckman Coulter DU® 730 Life Science UV/Vis Spectrofotometer) in the range of 200-400 nm from the solution of atezolizumab prepared in 6 series in 1.50 mg.mL⁻¹ saline medium [21].

**UV/Vis Method:** The calibration curve has been established. In this direction, standard solution of atezolizumab at concentration of 0.10, 0.25, 0.50, 0.75, 1.00 and 1.50 mg.mL⁻¹ were prepared and measured using a Beckman Coulter DU® 730 Life Science UV/Vis Spectrofotometer using the maximum wavelength ($\lambda_{\text{max}}$), previously determined.

**Validation:** Validation studies were carried out to determine the reliability of the spectrophotometer method used in quantification of pharmaceutical products. Thus, linearity, accuracy, precision (repeatability), durability (stability), specificity (selectivity), consistency, robustness, LOD and LOQ (sensitivity) were determined, as preconized FDA [22,23].

**Validation Parameters**

**Linearity**
The calibration curve has been determined according to Jaccoulet et al. [21]. In this direction atezolizumab at concentrations of 0.10, 0.25, 0.50, 0.75, 1.00 and 1.50 mg.mL⁻¹ (n = 6) were prepared, and the absorbance of each sample were determined by UV/Vis (Beckman Coulter DU® 730 Life Science UV/Vis Spectrofotometer). Finally, the $r^2$ were calculated to establish the correlation parameter.

**Accuracy**
To show the accuracy, the concentration used and the calculated one for 3 points (0.10, 0.75 and 1.50 mg.mL⁻¹) were selected. The accuracy value was determined as percent (%) both intraday and inter-days (Eq. 1).
(Eq. 1): (Practically calculated average concentration value / theoretically calculated concentration value) × 100

**Precision (Repeatability)**
For repeatability, at the concentrations of 0.10, 0.75 and 1.50 mg.mL⁻¹ atezolizumab solution was prepared, and UV/Vis absorbance was measured 5 times consecutively from the same sample both intraday and inter-days. As a result of these measurements, the area values of atezolizumab were compared and means, standard deviations and relative standard deviations were calculated.

**Durability (Stability)**
Six parallel standard solutions of a 0.75 mg.mL⁻¹ concentration of atezolizumab were prepared and their absorbance at UV/Vis was measured in the same order at the start time and 24-h after waiting at 4°C.

**Originality (Selectivity)**
To determine whether the analytical method used for the determination of the specificity of the substance belongs only to atezolizumab, the absorbance in UV/Vis of the solution containing atezolizumab and no atezolizumab was measured and the obtained spectrums were examined.

**Consistency**
The consistency of the method was tested by comparing the results obtained from the absorbance measured in UV/Vis of a 0.75 mg.mL⁻¹ medium concentration of atezolizumab, prepared by two different individuals.

**Robustness**
The robustness of the method was tested by comparing the results obtained by changing and measuring conditions and optimized conditions of atezolizumab at a medium concentration of 0.75 mg.mL⁻¹ in UV/Vis.

**Sensitivity**
Whether the developed method is sensitive enough for atezolizumab was evaluated by calculating LOD and LOQ.

**Statistical analysis**
Statistical analysis and variance analyze (Univariate Variance Analyze) of all the obtained results were done using SPSS software version 25. The statistical significance level was accepted as P < 0.05 for all analyses performed. Results were obtained in triplicate and presented as the mean ± SD.

**Results and Discussion**

**UV/Vis Spectrum**
The maximum absorbance for atezolizumab has been determined and the value found was 280 nm (Figure 1). This is the first time that this value has been described.

![Figure 1. UV/Vis spectrum of atezolizumab.](image)

Considering the protein structure from the monoclonal antibody, which usually have a $\lambda_{max}$ varying from 245-300 nm [21,24-27], our data (280 nm) is quite consistent. Also, we believe that this data will contribute to the literature and help researchers around the world to easily determine atezolizumab in the nanosystems.
Validation studies were carried out to determine the reliability of the spectrophotometer method used in quantification. Linearity, accuracy, precision (repeatability), durability (stability), specificity (selectivity), consistency, robustness and sensitivity were determined as validation parameters according to the criteria recommended by the FDA [22,23,28,29].

Validation parameters

Linearity

For the linearity parameter, 6 different concentrations of atezolizumab solution were prepared by diluting the stock solution and their absorbance in UV/Vis was measured. The calibration curve drawn with the help of the obtained absorbance values are shown in Figure 2. The line equation was $y = 1.4542x - 0.0397$ and the $r^2$ value 0.9995. This value indicates that the line shows 99.95% linearity [22,23].

Accuracy

To demonstrate the accuracy of the analytical method used, the absorbance values measured by UV/Vis analysis both intraday and inter-days were measured based on the amount of atezolizumab prepared at known concentrations (0.10, 0.75 and 1.50 mg.mL$^{-1}$) and its proximity to the actual value was determined as a percentage (%) accuracy value. The data obtained are shown in Table 1 and Table 2.

Table 1. Intraday accuracy values (%) calculated for atezolizumab.

| Concentration Values (mg.mL$^{-1}$) | 0.10 mg.mL$^{-1}$ | 0.75 mg.mL$^{-1}$ | 1.50 mg.mL$^{-1}$ |
|-------------------------------------|-------------------|-------------------|-------------------|
| Average                             | 0.098             | 0.752             | 1.477             |
| SD                                  | 0.002             | 0.004             | 0.005             |
| RSD (%)                             | 1.793             | 0.543             | 0.350             |
| Accuracy (%)                        | 97.67             | 100.22            | 98.44             |

As a result of the six parallel injections at the same concentration, the intraday and inter-days (%) accuracy values are 97.67, 100.22, 98.44% and 98.33, 100.22, 98.67%, respectively. In the statistical evaluation, no significant difference was observed between the intraday and inter-days accuracy values calculated from six injections for each concentration, as well as between low, medium, and high concentrations (P > 0.05). The expected accuracy value should be greater than 80% in the validation studies carried out by the FDA and the relative error should not be higher than 2. So, the accuracy study met this criterion [22,23].

Precision (Repeatability)

For repeatability, atezolizumab solution was prepared at 0.10, 0.75 and 1.50 mg.mL$^{-1}$ concentrations and UV/Vis measurement were performed 5 times consecutively from the same sample both intraday and inter-days. As a result of these measurements, the average, standard
deviation, and relative standard deviation values calculated by comparing the area values of atezolizumab are given in Table 3 and Table 4.

The percentage (%) of RSD values were calculated (1.333, 0, 0.371% and 0.557, 0.560, 0.371%) intraday and inter-days, respectively, and were found within the desired limits (not higher than 2) for each concentration [22,23].

Table 3. Intraday repeatability values (%) calculated for atezolizumab.

| Concentration Values (mg.mL⁻¹) | 0.10 mg.mL⁻¹ | 0.75 mg.mL⁻¹ | 1.50 mg.mL⁻¹ |
|--------------------------------|---------------|---------------|---------------|
| Average                        | 0.098         | 0.75          | 1.476         |
| SD                             | 0.001         | 0             | 0.005         |
| RSD (%)                        | 1.333         | 0             | 0.371         |
| Accuracy (%)                   | 97.80         | 100.00        | 98.40         |

Table 4. Inter-days repeatability values (%) calculated for atezolizumab.

| Concentration Values (mg.mL⁻¹) | 0.10 mg.mL⁻¹ | 0.75 mg.mL⁻¹ | 1.50 mg.mL⁻¹ |
|--------------------------------|---------------|---------------|---------------|
| Average                        | 0.098         | 0.748         | 1.476         |
| SD                             | 0.001         | 0.004         | 0.005         |
| RSD (%)                        | 0.557         | 0.560         | 0.371         |
| Accuracy (%)                   | 98.40         | 99.73         | 98.40         |

**Durability (Stability)**

6 parallel standard solutions of atezolizumab at 0.75 mg.mL⁻¹ concentration were prepared and their absorbance in UV/Vis was measured at the start time (0-h) and 24-h in the same order. The results obtained were given at Table 5.

Table 5. Stability test results.

| Time (h) | Initial (0-h) | 24-h |
|----------|---------------|------|
| Average  | 0.75 mg.mL⁻¹  | 0.748 mg.mL⁻¹ |
| SD       | 0             | 0.004 |
| RSD (%)  | 0             | 0.546 |
| Accuracy | 100.00        | 99.78 |

The RSD values were found to be 0% and 0.546%, respectively, according to the results obtained from the injections made at the time of start (0-h) and 24-h. It has been suggested by the FDA that % RSD values should be less than 20% for low concentrations and 15% for medium and high concentrations. Accordingly, % RSD values were found within the desired limits [22,23].

**Originality (Selectivity)**

To determine whether the analytical method used for the determination of the originality of the substance belongs only to atezolizumab, the absorbance of the saline solution containing atezolizumab and no atezolizumab in UV/Vis was measured and the spectra obtained are given in Figure 1 and Figure 3.

![Figure 3. Spectrum of solution without atezolizumab.](image)

The parameter of the specificity showed a maximum absorbance peak at 280 nm (Figure 1) corresponding to atezolizumab. Nonetheless, the sample free of atezolizumab showed no peak (Figure 3), indicating the selectivity of the method as preconized by FDA [22,23].

**Consistency**

The consistency of the method was evaluated by comparing the average of the results obtained from the absorbance measured in UV/Vis of atezolizumab at the medium concentration of 0.75 mg.mL⁻¹ prepared by two different people and there was no statistically
significant difference between the averages (P > 0.05). Thus, consistency parameter meets the FDA criteria [22,23].

**Robustness**
The robustness of the method was tested by comparing the results obtained by changing the conditions and repeating the measurement (from the medium concentration of 0.75 mg.mL⁻¹) using UV/Vis. The results obtained from optimized conditions were evaluated and no statistically significant difference between the averages (P > 0.05) were found. The data corroborates the high robustness of the methodology [22,23].

**Sensitivity**
Whether the developed method is sensitive enough for atezolizumab was evaluated by calculating the limit of detection (LOD) and limit of quantification (LOQ). The results are given in Table 6. The LOD value of the atezolizumab was found to be 0.005 mg.mL⁻¹ and a LOQ value of the atezolizumab was found to be 0.018 mg/ml using the lowest atezolizumab concentration possible (Table 6).

| Parameter | Concentration Value (mg.mL⁻¹) |
|-----------|-------------------------------|
| Linearity Range | 0.10-1.50 mg.mL⁻¹ |
| LOD | 0.005 mg.mL⁻¹ |
| LOQ | 0.018 mg.mL⁻¹ |

The sensitivity parameter, which has the ability to distinguish small deviations in the concentration of active substance or to detect low concentrations of the active substance, was found to be sensitive enough for atezolizumab.

**Conclusion**
As a result of all the parameters obtained, the UV/Vis method was found to be linear, highly accurate, reproducible, stable, unique, consistent, high robust and sensitive according to the criteria specified by the FDA. These data show that the developed UV/Vis spectroscopy method is a suitable method for quantitatively determining the amount of atezolizumab in pharmaceutical products and also in commercial samples, various dosage forms and rat-mice blood/plasma and human specimens.

**Funding:** This study was supported by The Scientific and Technological Research Council of Turkey (TUBITAK-220/S/361) within the scope of PhD thesis of Meliha Ekinci.

**Conflict of Interest:** The authors declare that they have no conflict of interest.

**Ethical statement:** Ethics committee decision was not taken as it was a spectroscopy method.

**Open Access Statement**
Experimental Biomedical Research is an open access journal and all content is freely available without charge to the user or his/her institution. This journal is licensed under a [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/). Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author.

**Copyright (c) 2021:** Author(s).

**References**
[1] Sau S, Petrovici A, Alsaab HO, et al. PDL-1 antibody drug conjugate for selective Chemo-guided immune modulation of cancer. Cancers (Basel). 2019; 11(2): 232.
[2] Deng R, Bumbaca D, Pastuskovas CV, et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune
checkpoint inhibitor. MAbs. 2016; 8(3): 593–603.

[3]Atezolizumab. In: FDA label. [cited 2020 May 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761034s014lbl.pdf

[4]Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012; 12: 14.

[5]Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: Present and promise. Crit Rev Oncol Hematol. 2005; 54(1): 11–29.

[6]Martinelli E, De Palma R, Orditura M, et al. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol. 2009; 158(1): 1–9.

[7]Chari RVJ. Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc Chem Res. 2008; 41(1): 98–107.

[8]Ordás I, Mould DR, Feagan BG et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: Pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012; 91(4): 635–46.

[9]Liu JKH. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Ann Med Surg. 2014; 3(4): 113–16.

[10]Heremans H, Dillen C, Groenen M, et al. Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: Enhancement by monoclonal antibodies against interferon-γ. Eur J Immunol. 1996; 26(109): 2393–98.

[11]Mauri C, Mars LT, Londei M. Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process. Nat Med. 2000; 6(6): 673–79.

[12]Cerqueira-Coutinho C, Missailidis S, Alessandra-Perini J, et al. Comparison of biodistribution profile of monoclonal antibodies nanoparticles and aptamers in rats with breast cancer. Artif Cells Nanomedicine Biotechnol. 2017; 45(3): 598–601.

[13]Allan PM, Garson JA, Harper EI, et al. Biological characterization and clinical applications of a monoclonal antibody recognizing an antigen restricted to neuroectodermal tissues. Int J Cancer. 1983; 31(5): 591–98.

[14]Ligiero T, Souza Albernaz M, de Carvalho S, et al. Monoclonal antibodies: Application in radiopharmacy. Curr Radiopharm. 2014; 6(4): 231–48.

[15]Helal-Neto E, Cabezas SS, Sancenón F, et al. Indirect calculation of monoclonal antibodies in nanoparticles using the radiolabeling process with technetium 99 metastable as primary factor: Alternative methodology for the entrapment efficiency. J Pharm Biomed Anal. 2018; 153: 90–94.

[16]Jadhav K, Dhamecha D, Tate A, et al. Application of UV spectrophotometric method for easy and rapid estimation of lafutidine in bulk and pharmaceutical formulation. Pharm Methods. 2011; 2(4): 264–67.

[17]Babu D, Chetty C, Mastanamma S. Stability indicating RP-HPLC method development and validation for the estimation of atezolizumab in bulk and its injectable dosage form. J Pharm Res Int. 2017; 18(5): 1–9.

[18]Goyon A, Francois YN, Colas O, et al. High-resolution separation of monoclonal antibodies mixtures and their charge variants by an alternative and generic CZE method. Electrophoresis. 2018; 39(16): 2083–90.

[19]He J, Meng L, Ruppel J, et al. Automated, generic reagent and ultratargeted 2D-LC-MS/MS enabling quantification of
biotherapeutics and soluble targets down to pg/mL range in serum. Anal. Chem. 2020; 92(13): 9412–20.

[20] Ehkirch A, Hernandez-Alba O, Colas O, et al. Hyphenation of size exclusion chromatography to native ion mobility mass spectrometry for the analytical characterization of therapeutic antibodies and related products. J Chromatogr B Anal Technol Biomed Life Sci. 2018; 1086: 176–83.

[21] Jaccoulet E, Schweitzer-Chaput A, Toussaint B, et al. Simple and ultra-fast recognition and quantitation of compounded monoclonal antibodies: Application to flow injection analysis combined to UV spectroscopy and matching method. Talanta. 2018; 187: 279–86.

[22] FDA. Food and Drug Administration. Guidance for industry: Bionalytical Methods Validation for Human Studies. US Department of Health. 1998.

[23] FDA. Food and Drug Administration. Guidance for industry: Analytical Procedures and Methods Validation Chemistry, Manufacturing and Controls Documentation. US Department of Health. 2000.

[24] Jaccoulet E, Boccard J, Taverna M, et al. High-throughput identification of monoclonal antibodies after compounding by UV spectroscopy coupled to chemometrics analysis. Anal Bioanal Chem. 2016; 408(21): 5915–24.

[25] Kueltzo LA, Middaugh CR. Structural characterization of bovine granulocyte colony stimulating factor: Effect of temperature and pH. J Pharm Sci. 2003; 92(9): 1793–1804.

[26] Lucas LH, Ersoy BA, Kueltzo LA, et al. Probing protein structure and dynamics by second-derivative ultraviolet absorption analysis of cation-π interactions. Protein Sci. 2006; 15(10): 2228–43.

[27] Mach H, Middaugh CR. Ultraviolet spectroscopy as a tool in therapeutic protein development. J Pharm Sci. 2011; 100(4): 1214-27.

[28] Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies. Eur J Drug Metab Pharmacokinet. 1991; 16(4): 249–55.

[29] Feinberg M. Validation of analytical methods based on accuracy profiles. J Chromatogr A. 2007; 1158(1-2): 174–83.